Preliminary results indicate that anti-BCMA CAR-T cell therapy, ciltacabtagene autleucel (cilta-cel), resulted in early, deep and durable responses in heavily pre-treated patients with MM. ORR was , sCR . Durability of response at data cut-off was Additional studies in MM are ongoing.
Log In with AHPRA